HRP20220215T1 - Inhibitori mcl-1 - Google Patents

Inhibitori mcl-1 Download PDF

Info

Publication number
HRP20220215T1
HRP20220215T1 HRP20220215TT HRP20220215T HRP20220215T1 HR P20220215 T1 HRP20220215 T1 HR P20220215T1 HR P20220215T T HRP20220215T T HR P20220215TT HR P20220215 T HRP20220215 T HR P20220215T HR P20220215 T1 HRP20220215 T1 HR P20220215T1
Authority
HR
Croatia
Prior art keywords
image
alkyl
heteroalkyl
cycloalkyl
membered heterocyclyl
Prior art date
Application number
HRP20220215TT
Other languages
English (en)
Inventor
Hang CHU
Juan A. Guerrero
Anna E. Hurtley
Tae H. Hwang
Lan Jiang
Darryl Kato
Tetsuya Kobayashi
John E. Knox
Scott E. Lazerwith
Xiaofen Li
David W. Lin
Jonathan W. Medley
Michael L. Mitchell
Devan Naduthambi
Zachary NEWBY
Neil H. Squires
Vickie H. Tsui
Chandrasekar Venkataramani
William J. Watkins
Hong Yang
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of HRP20220215T1 publication Critical patent/HRP20220215T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Claims (15)

1. Spoj, naznačen time, da je u skladu s Formulom (I): [image] u kojoj: --- je jednostruka ili dvostruka veza: X je O ili NR7; R12 je vodik ili -C(O)R1; R1 je C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, C3-10 cikloalkil, C6-10 aril, 3-12-člani heterociklil, 5-10-člani heteroaril, -OR7 ili -NR8R9, pri čemu su navedeni C1-6 alkil, C2-6 alkinil, C3-10 cikloalkil, C6-10 aril, 3-12-člani heterociklil i 5-10-člani heteroaril, opcionalno supstituirani s 1-5 skupina R10; R2 je vodik, C1-6 alkil, C1-6 heteroalkil, C3-10 cikloalkil ili 3-12-člani heterociklil, gdje su navedeni C1-6 alkil, C1-6 heteroalkil, C3-10 cikloalkil i 3-12-člani heterociklil, opcionalno supstituirani s 1-5 skupina R10; R3 i R4 su neovisno vodik, C1-6 alkil, -OR7, C1-6 heteroalkil, -NR8R9, -NR8C(O)R9, -NR8C(O)OR9, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril, 3-12-člani heterociklil, -C(O)R7, -C(O)OR7, -C(O)NR8R9, -OC(O)NR8R9, -CN ili -SO2R7, pri čemu su navedeni C1-6 alkil, C1-6 heteroalkil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril i 3-12-člani heterociklil, opcionalno supstituirani s 1-5 skupina R10; R5 je vodik, C1-6 alkil, -(CH2CH2O)pR7, C1-6 heteroalkil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril ili 3-12-člani heterociklil, pri čemu su navedeni C1-6 alkil, C1-6 heteroalkil, C6-10 aril, C3-10 cikloalkil, 5-10-člani heteroaril i 3-12-člani heterociklil, opcionalno supstituirani s 1-5 skupina R10; R6 je vodik ili halogen; svaki R7 je neovisno vodik, C1-6 alkil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril ili 5-10-člani heteroaril, pri čemu su navedeni C1-6 alkil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril i 5-10-člani heteroaril, opcionalno supstituirani s 1-5 skupina R10; svaki R8 i R9 je neovisno vodik, C1-6 alkil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril ili 5-10-člani heteroaril, ili R8 i R9 zajedno s atomima s kojima su vezani, tvore 3-12-člani heterociklil, pri čemu su navedeni C1-6 alkil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril i 5-10-člani heteroaril, opcionalno supstituirani s 1-5 skupina R10; svaki R10 je neovisno C1-6 alkil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril, 5-10-člani heteroaril, halogen, okso, -ORa, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, -S(O)qRa, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN ili NO2, ili dvije skupine R10 tvore staljeni, spiro ili premošteni C3-10 cikloalkil ili 3-12-člani heterociklil, pri čemu je svaki C1-6 alkil, C1-6 heteroalkil, C2-6 alkinil, C3-10 cikloalkil, C6-10 aril, 3-12-člani heterociklil i 5-10-člani heteroaril, opcionalno supstituiran s 1-5 skupina R20; svaki Ra i Rb je neovisno vodik, C1-6 alkil, C2-6 alkenil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril, 5-10-člani heteroaril, ili Ra i Rb zajedno s atomima s kojima su vezani, tvore 3-12-člani heterociklil, pri čemu je navedeni C1-6 alkil, C2-6 alkenil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril, 5-10-člani heteroaril, opcionalno supstituiran s 1-5 skupina R20; svaki R20 je neovisno C1-6 alkil, C3-10 cikloalkil, C1-6 heteroalkil, 3-12-člani heterociklil, C6-10 aril, 5-10-člani heteroaril, hidroksil, C1-6 alkoksi, amino, -CN, -C(O)H, -C(O)NH2, -C(O)NH(C1-6 alkil), -C(O)N(C1-6 alkil)2, -COOH, -C(O)C1-6 alkil, -C(O)OC1-6 alkil ili halogen; n je 0, 1 ili 2; p je 0, 1 ili 2; i q je 0, 1 ili 2; ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je u skladu s Formulom (IV): [image] u kojoj: R1 je C3-10 cikloalkil, 3-12-člani heterociklil, C6-10 aril ili 5-10-člani heteroaril; pri čemu je R1 neovisno opcionalno supstituiran s 1-4 skupine R10; gdje se svaki R10 neovisno bira od sljedećih: halogen, hidroksil, -CN, C1-6 alkil, C1-6 heteroalkil, C3-10 cikloalkil i 3-12-člani heterociklil; pri čemu su C1-6 alkil, C1-6 heteroalkil, C3-10 cikloalkil i 3-12-člani heterociklil od R10, neovisno opcionalno supstituirani s 1-4 supstituenta koji se neovisno biraju od halogena, C1-4 alkila, C1-4 haloalkila i C1-4 heteroalkila; R2 je vodik, C1-6 alkil ili C1-6 heteroalkil; pri čemu su C1-6 alkil i C1-6 heteroalkil od R2, opcionalno supstituirani s 1-3 supstituenta koji se neovisno biraju od halogena, okso i hidroksila; R3 i R4 su neovisno vodik, C1-6 alkil, C1-6 heteroalkil, -OR7 ili -SO2R7; pri čemu su C1-6 alkil i C1-6 heteroalkil od R3 i R4, neovisno opcionalno supstituirani s 1-3 supstituenta koji se neovisno biraju od halogena, okso, C3-6 cikloalkila, 4-6-članog heterociklila, C6-10 arila i 5-10-članog heteroarila; dok su C3-6 cikloalkil, 4-6-člani heterociklil, C6-10 aril i 5-10-člani heteroaril, neovisno opcionalno supstituirani s 1-3 supstituenta koji se neovisno biraju od halogena, C1-4 alkila i C1-4 heteroalkila; R5 je vodik, C1-6 alkil ili C1-6 heteroalkil; pri čemu su C1-6 alkil i C1-6 heteroalkil od R5, opcionalno supstituirani s 1-3 supstituenta koji se neovisno biraju od halogena, okso, C3-6 cikloalkila i 4-6-članog heterociklila; i R7 je neovisno vodik, C1-6 alkil, C1-6 heteroalkil, C3-10 cikloalkil, 3-10-člani heterociklil, C6-10 aril ili 5-10-člani heteroaril; pri čemu su C1-6 alkil, C1-6 heteroalkil, C3-10 cikloalkil, 3-10-člani heterociklil, C6-10 aril i 5-10-člani heteroaril od R7, opcionalno supstituirani s 1-4 supstituenta koji se neovisno biraju od halogena, okso, C1-4 alkila, C1-4 haloalkila i C1-4 heteroalkila.
3. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da: R2 je vodik ili C1-3 alkil; R3 je vodik ili C1-3 alkil; R4 je vodik; R5 je C1-3 alkil, gdje je navedeni C1-3 alkil opcionalno supstituiran s 5-6-članim heterociklilom; ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da: R2 je vodik, metil ili etil; R3 je vodik ili metil; R4 je vodik; i R5 je vodik, metil, [image] ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 je metil.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R4 je vodik.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R5 je metil.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R1 je [image] supstituiran s dvije skupine koje se biraju od C1-4 alkila i C1-4 alkoksila.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R1 je [image]
10. Spoj prema bilo kojem od patentnih zahtjeva 1 i 3 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se R1 bira od: [image] [image] [image] [image] [image] [image] [image]
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se bira od: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9 i 11, naznačen time, da je: [image] ili njegova farmaceutski prihvatljiva sol.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7 i 11, naznačen time, da je: [image] ili njegova farmaceutski prihvatljiva sol.
14. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9 i 11 do 13, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivo pomoćno sredstvo.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9 i 11 do 13, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema patentnom zahtjevu 14, naznačen time, da je za uporabu u postupku liječenja raka kod pacijenta, pri čemu to obuhvaća davanje pacijentu spoja, njegove farmaceutski prihvatljive soli, ili farmaceutskog pripravka.
HRP20220215TT 2018-05-14 2019-05-13 Inhibitori mcl-1 HRP20220215T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671306P 2018-05-14 2018-05-14
US201862749918P 2018-10-24 2018-10-24
PCT/US2019/032053 WO2019222112A1 (en) 2018-05-14 2019-05-13 Mcl-1 inhibitors
EP19728793.1A EP3793565B1 (en) 2018-05-14 2019-05-13 Mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
HRP20220215T1 true HRP20220215T1 (hr) 2022-04-29

Family

ID=66770559

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220215TT HRP20220215T1 (hr) 2018-05-14 2019-05-13 Inhibitori mcl-1

Country Status (29)

Country Link
US (4) US10703733B2 (hr)
EP (2) EP4029868A1 (hr)
JP (3) JP6899975B2 (hr)
KR (2) KR102551319B1 (hr)
CN (2) CN117304130A (hr)
AU (3) AU2019269391B2 (hr)
BR (1) BR112020021648A2 (hr)
CA (1) CA3099152C (hr)
CL (1) CL2020002919A1 (hr)
CO (1) CO2020014009A2 (hr)
CR (1) CR20200544A (hr)
CY (1) CY1125065T1 (hr)
DK (1) DK3793565T3 (hr)
ES (1) ES2907923T3 (hr)
HR (1) HRP20220215T1 (hr)
HU (1) HUE057852T2 (hr)
IL (2) IL291430B2 (hr)
LT (1) LT3793565T (hr)
MX (1) MX2020012137A (hr)
PE (1) PE20210004A1 (hr)
PH (1) PH12020551881A1 (hr)
PL (1) PL3793565T3 (hr)
PT (1) PT3793565T (hr)
SG (1) SG11202010964VA (hr)
SI (1) SI3793565T1 (hr)
TW (2) TWI813957B (hr)
UA (1) UA125163C2 (hr)
WO (1) WO2019222112A1 (hr)
ZA (1) ZA202007007B (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057852T2 (hu) 2018-05-14 2022-06-28 Gilead Sciences Inc MCL-1 inhibítorok
US20240067660A1 (en) 2019-07-09 2024-02-29 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) * 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020391106B2 (en) 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
WO2021211922A1 (en) * 2020-04-16 2021-10-21 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
JP2023528965A (ja) 2020-06-10 2023-07-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としての大環状２－アミノ－３－フルオロ－ブタ－３－エナミド
AU2021381769A1 (en) * 2020-11-19 2023-06-22 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
MX2023007297A (es) 2020-12-17 2023-07-04 Janssen Pharmaceutica Nv 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4330262A1 (en) 2021-04-26 2024-03-06 JANSSEN Pharmaceutica NV Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
WO2023088894A1 (en) 2021-11-16 2023-05-25 Janssen Pharmaceutica Nv Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230357274A1 (en) * 2022-05-04 2023-11-09 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
DK1761540T3 (en) 2004-05-13 2016-11-21 Icos Corp Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
BRPI0808888B8 (pt) 2007-03-12 2021-05-25 Cytopia Res Pty Ltd composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
JP5659014B2 (ja) 2007-08-02 2015-01-28 ジリード バイオロジクス，インク． 線維症、腫瘍浸潤、血管新生及び転移の治療及び診断のための方法及び組成物
DK2604693T3 (en) 2008-07-21 2016-05-30 Apogenix Gmbh Single-chain TNFSF molecules
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PT2608809T (pt) 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
KR102062407B1 (ko) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
AR092662A1 (es) 2012-09-24 2015-04-29 Gilead Sciences Inc Anticuerpos anti-ddr1
EP2935246B1 (en) 2012-12-21 2018-07-25 Gilead Calistoga LLC Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
AR096621A1 (es) 2013-06-14 2016-01-20 Gilead Sciences Inc Inhibidores de isómeros de la fosfatidilinositol 3-quinasa (pi3k)
US9657023B2 (en) 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
CN106456602B (zh) * 2014-03-27 2020-11-24 范德比尔特大学 取代的吲哚mcl-1抑制剂
CA2945305C (en) 2014-04-10 2023-10-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method and compositions for cellular immunotherapy
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
ES2727376T3 (es) 2014-09-26 2019-10-15 Gilead Sciences Inc Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
MX2017007138A (es) 2014-12-03 2017-08-28 Juno Therapeutics Inc Metodos y composiciones para terapia celular adoptiva.
US20160166613A1 (en) 2014-12-15 2016-06-16 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
KR20180004811A (ko) 2015-05-15 2018-01-12 길리애드 사이언시즈, 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서의 활성을 갖는 벤즈이미다졸 및 이미다조피리딘 카르복스이미드아미드 화합물
CA2986060A1 (en) 2015-05-29 2016-12-08 Valerie Odegard Composition and methods for regulating inhibitory interactions in genetically engineered cells
IL297003A (en) 2015-09-17 2022-12-01 Novartis Ag car-t cell treatments with improved efficacy
WO2017147410A1 (en) * 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
WO2019036575A1 (en) 2017-08-18 2019-02-21 Amgen Inc. MCL-1 PROTEIN INHIBITING COMPOUNDS
EP3676270A1 (en) 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
EP3697410A4 (en) 2017-10-19 2021-08-11 Amgen Inc. BENZIMIDAZOLE DERIVATIVES AND THEIR USES
US11274105B2 (en) 2018-03-05 2022-03-15 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
IL309891A (en) 2018-05-14 2024-03-01 Reata Pharmaceuticals Inc Bi-aryl amides with sugar groups that are adapted to the treatment of related diseases
HUE057852T2 (hu) 2018-05-14 2022-06-28 Gilead Sciences Inc MCL-1 inhibítorok
EP3793547A4 (en) 2018-05-15 2021-11-17 H. Lundbeck A/S MAGL INHIBITORS
US20220356174A1 (en) 2018-07-24 2022-11-10 Epizyme, Inc. Pyridin-2-one compounds useful as smarca2 antagonists
AU2019374907A1 (en) 2018-11-09 2021-06-03 Prelude Therapeutics, Incorporated Spiro-sulfonamide derivatives as inhibitors of Myeloid Cell Leukemia-1 (Mcl-1) protein
US11498928B2 (en) 2019-01-18 2022-11-15 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as Mcl-1 inhibitors
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020391106B2 (en) 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
JP2021161114A (ja) 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
BR112022022400A2 (pt) 2020-05-06 2022-12-13 Amgen Inc Síntese de intermediários de álcool vinílico protegidos
JP2023528965A (ja) 2020-06-10 2023-07-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としての大環状２－アミノ－３－フルオロ－ブタ－３－エナミド
AU2021306644A1 (en) 2020-07-08 2023-03-09 Janssen Pharmaceutica Nv Macrocyclic ether containing indole derivatives as inhibitors of MLC-1
AU2021381769A1 (en) 2020-11-19 2023-06-22 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors

Also Published As

Publication number Publication date
KR102551319B1 (ko) 2023-07-05
US20200331870A1 (en) 2020-10-22
HUE057852T2 (hu) 2022-06-28
AU2019269391B2 (en) 2021-02-25
AU2023270332A1 (en) 2023-12-14
CL2020002919A1 (es) 2021-04-16
IL278336B (en) 2022-04-01
JP7240431B2 (ja) 2023-03-15
US10703733B2 (en) 2020-07-07
CN112118845B (zh) 2023-06-13
BR112020021648A2 (pt) 2021-01-26
IL291430B1 (en) 2023-12-01
SG11202010964VA (en) 2020-12-30
SI3793565T1 (sl) 2022-04-29
KR20230107889A (ko) 2023-07-18
PH12020551881A1 (en) 2021-05-31
EP3793565A1 (en) 2021-03-24
PE20210004A1 (es) 2021-01-05
CN112118845A (zh) 2020-12-22
EP4029868A1 (en) 2022-07-20
CO2020014009A2 (es) 2020-11-30
UA125163C2 (uk) 2022-01-19
AU2021203373B2 (en) 2023-09-14
US20230312490A1 (en) 2023-10-05
JP2021098728A (ja) 2021-07-01
LT3793565T (lt) 2022-02-25
US11643400B2 (en) 2023-05-09
DK3793565T3 (en) 2022-03-07
ZA202007007B (en) 2023-11-29
TWI813957B (zh) 2023-09-01
EP3793565B1 (en) 2022-01-05
TW202122403A (zh) 2021-06-16
CA3099152C (en) 2023-10-24
PT3793565T (pt) 2022-04-13
WO2019222112A1 (en) 2019-11-21
CR20200544A (es) 2021-02-11
IL291430B2 (en) 2024-04-01
MX2020012137A (es) 2021-01-29
KR20210006981A (ko) 2021-01-19
AU2019269391A1 (en) 2020-11-19
WO2019222112A8 (en) 2020-11-12
CA3099152A1 (en) 2019-11-21
US20190352271A1 (en) 2019-11-21
US20220340535A1 (en) 2022-10-27
IL291430A (en) 2022-05-01
JP6899975B2 (ja) 2021-07-07
PL3793565T3 (pl) 2022-05-02
CY1125065T1 (el) 2023-06-09
ES2907923T3 (es) 2022-04-27
US10988451B2 (en) 2021-04-27
CN117304130A (zh) 2023-12-29
JP2023060145A (ja) 2023-04-27
AU2021203373A1 (en) 2021-06-24
TWI719478B (zh) 2021-02-21
TW202010740A (zh) 2020-03-16
JP2021515030A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
HRP20220215T1 (hr) Inhibitori mcl-1
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
HRP20191414T1 (hr) Novi spojevi i derivati spiro[3h-indol-3,2'-pirolidin]-2(1h)-ona kao mdm1-p53-inhibitori
AR062881A1 (es) N-hidroxiamidinoheterociclos como moduladores de indolamina-2,3-dioxigenasa
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20211124T1 (hr) TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI
AR081830A1 (es) Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos
HRP20161786T1 (hr) Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
IL274568B (en) Modulators of cot and methods of using them
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
JP2014518882A5 (hr)
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
RS54180B1 (en) FUSIONAL HETEROAROMATIC PYROLIDINONS AS SYK INHIBITORS
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
SI3099687T1 (en) MACROCYCLES WITH HETEROCYCLIC P2 'GROUPS AS FACTOR XIA INHIBITORS
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
IL272762B1 (en) Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases
JP2009504764A5 (hr)
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2016506959A5 (hr)
FI3697784T3 (fi) Imidatso[4,5-b]pyridiiniyhdisteet ja niiden farmaseuttiset koostu- mukset tulehduksellisten häiriöiden hoitoa varten
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
AR084730A1 (es) Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos
SI2797921T1 (en) Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors